Gamco Investors INC. ET AL Has $3.75 Million Position in LGL Group, Inc. (The) $LGL

Gamco Investors INC. ET AL lowered its stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 31.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 652,476 shares of the industrial products company’s stock after selling 301,398 shares during the period. Gamco Investors INC. ET AL owned 0.12% of LGL Group worth $3,752,000 at the end of the most recent quarter.

Separately, Citadel Advisors LLC bought a new position in LGL Group in the third quarter valued at approximately $90,000. 30.28% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Zacks Research raised shares of LGL Group to a “hold” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold”.

LGL Group Stock Performance

Shares of LGL stock opened at $7.01 on Thursday. LGL Group, Inc. has a 52-week low of $5.45 and a 52-week high of $9.74. The stock has a market cap of $45.85 million, a PE ratio of 701.70 and a beta of 0.31. The firm’s 50 day moving average price is $7.09 and its two-hundred day moving average price is $6.62.

LGL Group (NYSEAMERICAN:LGL) last announced its quarterly earnings data on Monday, March 30th. The industrial products company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09). LGL Group had a net margin of 1.66% and a return on equity of 0.16%. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $9.10 million. As a group, sell-side analysts predict that LGL Group, Inc. will post 0.06 earnings per share for the current fiscal year.

LGL Group Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.